Proteins from actinobacillus pleuropneumoniae
AssigneesPfizer Inc., Pfizer Products Inc.
InventorsRobert G. Ankenbauer, Mary Jo Baarsch, Manuel Campos, Robin Keich, Everett Rosey, Brian Suiter, Lynn Warren-Stewart
Life of this patent
Estimating the term…
Abstract
The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.
Claims5
A vaccine against Actinobacillus pleuropneumoniae, comprising an immunologically effective amount of
- (a) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 172 of SEQ ID NO:2,
- (b) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 22 to amino acid residue 215 of SEQ ID NO:4,
- (c) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 28 to amino acid residue 258 of SEQ ID NO:6,
- (d) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 364 of SEQ ID NO:8, and
- (e) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 369 of SEQ ID NO:10;
- an adjuvant;
- and a veterinarily acceptable carrier or diluent.
A vaccine kit for vaccinating swine against APP, comprising a container comprising an immunologically effective amount of
- (a) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 172 of SEQ ID NO:2,
- (b) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 22 to amino acid residue 215 of SEQ ID NO:4,
- (c) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 28 to amino acid residue 258 of SEQ ID NO:6,
- (d) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 364 of SEQ ID NO:8, and
- (e) a substantially purified polypeptide comprising the amino acid sequence of amino acid residue 20 to amino acid residue 369 of SEQ ID NO:10;
- and an adjuvant.
Dependencies are inferred from the claim text.